Corium International, Inc. (NASDAQ:CORI) has received a consensus recommendation of “Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $10.30.
A number of equities research analysts recently issued reports on the company. WBB Securities raised Corium International to a “buy” rating in a research report on Friday. Zacks Investment Research raised Corium International from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research report on Tuesday, June 6th. ValuEngine raised Corium International from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $12.00 price target (up previously from $10.00) on shares of Corium International in a research report on Friday, May 12th. Finally, Jefferies Group LLC set a $8.00 price target on Corium International and gave the stock a “buy” rating in a research report on Thursday, April 20th.
WARNING: “Corium International, Inc. (CORI) Receives Average Rating of “Buy” from Analysts” was reported by WKRB News and is the property of of WKRB News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.wkrb13.com/markets/2286435/corium-international-inc-cori-receives-average-rating-of-buy-from-analysts.html.
Corium International (CORI) traded up 1.35% during midday trading on Monday, hitting $8.98. The company had a trading volume of 356,994 shares. The company’s 50 day moving average is $7.02 and its 200-day moving average is $4.78. The company’s market cap is $262.50 million. Corium International has a one year low of $2.67 and a one year high of $9.51.
Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.05. The company had revenue of $7.35 million for the quarter, compared to analyst estimates of $6.05 million. Corium International had a negative return on equity of 1,550.00% and a negative net margin of 116.59%. On average, equities analysts predict that Corium International will post ($1.69) EPS for the current year.
In other Corium International news, major shareholder Perceptive Advisors Llc bought 1,902,400 shares of Corium International stock in a transaction on Thursday, May 25th. The shares were purchased at an average price of $6.25 per share, with a total value of $11,890,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Maste Perceptive bought 301,004 shares of Corium International stock in a transaction on Friday, June 30th. The stock was acquired at an average cost of $7.71 per share, for a total transaction of $2,320,740.84. The disclosure for this purchase can be found here. Company insiders own 46.50% of the company’s stock.
Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its stake in shares of Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 13,683 shares in the last quarter. Royce & Associates LP increased its stake in shares of Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock worth $2,293,000 after buying an additional 370,600 shares in the last quarter. AWM Investment Company Inc. increased its stake in shares of Corium International by 1,125.9% in the first quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock worth $10,248,000 after buying an additional 2,251,700 shares in the last quarter. Broadfin Capital LLC increased its stake in shares of Corium International by 45.2% in the first quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock worth $11,650,000 after buying an additional 867,400 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in shares of Corium International during the first quarter worth $11,096,000. 77.47% of the stock is currently owned by hedge funds and other institutional investors.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286435/corium-international-inc-cori-receives-average-rating-of-buy-from-analysts.html
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.